Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age (ICICLE)

This study has suspended participant recruitment.
(Study recruitment has been suspended.)
Information provided by (Responsible Party):
MedImmune LLC Identifier:
First received: November 6, 2013
Last updated: September 6, 2016
Last verified: August 2016
This is a post-marketing case-controlled study of the effectiveness of a quadrivalent live attenuated influenza vaccine (Q/LAIV/FluMist® Quadrivalent) versus Inactivated Influenza Vaccine (IIV) and No Vaccine in subjects 2-17 years of age.

Condition Phase
Influenza Vaccine Effectiveness
Phase 4

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age

Resource links provided by NLM:

Further study details as provided by MedImmune LLC:

Primary Outcome Measures:
  • Identification of cases positive for wild-type influenza with an end-point PCR genotyping assay. [ Time Frame: Up to 6 months for each individual flu season ]
    Vaccine Effectiveness is defined as 100 x (1-odds ratio), where the odds ratio is the odds of exposures (Q/LAIV versus Inactivated Influenza Vaccine or no vaccine) among laboratory confirmed cases of flu versus controls. Effectiveness will be monitored by flu season, class of age and by influenza strain.

Biospecimen Retention:   Samples With DNA
A nasal swab specimen will be collected and tested for influenza and other viral pathogens.

Estimated Enrollment: 8760
Study Start Date: December 2013
Estimated Study Completion Date: April 2018
Estimated Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)
FluMist Quadrivalent
Inactivated Influenza Vaccine
Inactivated Influenza Vaccine

Detailed Description:
This post-marketing study will enroll approximately 5,200 subjects 2-17 years of age who are seeking care in an outpatient setting for febrile acute respiratory illness. This study will begin in the fall of 2013 and will be completed after 4 influenza seasons (i.e.after the 2016-2017 influenza season). No investigational product will be administered in this study. A nasal swab will be obtained and tested for the presence of influenza virus and other viral pathogens. This study will be conducted at 4 sites in the United States of America. The duration of study participation for each subject is one day.

Ages Eligible for Study:   2 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Subjects 2 to 17 years of age who are seeking care in an outpatient setting for febrile acute respiratory illness.

Inclusion Criteria:

  • Community-dwelling children and adolescents 2 to 17 years of age.
  • Written Informed Consent or Assent.
  • Acute respiratory illness documented at study visit or at home with fever (oral temperature ≥ 100.0° Fahrenheit at study visit, or history of fever reported by parents, or use of antipyretic prior to study visit)
  • Symptom onset less than 5 days prior to study visit.
  • Subject and/or subject's legal representative is able to understand and comply with the requirements of the protocol as judged by the investigator.

Exclusion Criteria:

  • Treatment with an antiviral drug for influenza (oseltamivir or Tamiflu®, zanamivir or Relenza®) during the 14 days before enrollment
  • Any condition that, in the opinion of the investigator, would interfere with interpretation of subject safety or study results
  • Concurrent enrollment in another clinical study

Patient already enrolled during this influenza season

  • Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01997450

United States, Florida
Research Site
Gainesville, Florida, United States
United States, Minnesota
Research Site
Bloomington, Minnesota, United States
United States, North Carolina
Research Site
Winston-Salem, North Carolina, United States
United States, Ohio
Research Site
Akron, Ohio, United States
United States, Oregon
Research Site
Portland, Oregon, United States
United States, Tennessee
Research Site
Nashville, Tennessee, United States
United States, Texas
Research Site
Temple, Texas, United States
United States, Wisconsin
Research Site
Marshfield, Wisconsin, United States
United Kingdom
Research Site
Bristol, United Kingdom
Research Site
Oxford, United Kingdom
Research Site
Southampton, United Kingdom
Research Site
Tooting, United Kingdom
Sponsors and Collaborators
MedImmune LLC
Study Director: Herve Caspard, MD MedImmune LLC
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: MedImmune LLC Identifier: NCT01997450     History of Changes
Other Study ID Numbers: MA-VA-MEDI3250-1116
Study First Received: November 6, 2013
Last Updated: September 6, 2016

Keywords provided by MedImmune LLC:
Q/LAIV/FluMist® Quadrivalent Vaccine, Inactivated Influenza Vaccine (IIV), Effectiveness, Influenza

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on April 28, 2017